Japan's Tanabe Pharma, Switzerland's Covagen In Biospecific-Protein Pact
This article was originally published in PharmAsia News
Executive Summary
Tanabe Pharma and Covagen have agreed to a collaboration and licensing arrangement the calls for the Japan drug maker to provide $5.2 million up front for research and development of the Swiss company's biospecific proteins. Under the arrangement,